Follow Us

header ads
header ads

Behavioral Rehabilitation Market is Anticipated to have Market Value of USD 215.6 Bn by 2030

 The global behavioral rehabilitation market size is expected to reach around US$ 215.6 billion by 2030 from US$ 150 billion in 2021 and is expected to grow at an impressive double-digit rate of 3.7% from 2021 to 2030.

Behavioral Rehabilitation Market Size 2021 to 2030

The study includes drivers and restraints of this market. The study provides an analysis of the global behavioral rehabilitation market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.

The rising prevalence of various mental disorders such as depression, anxiety, and attention deficit disorders are the primary drivers of the global behavioral rehabilitation market. According to the Mental Health Foundation, the most severe cause of increasing medical concerns is the mental health disorders. According to the US Department of Health and Human Services, around 20% of the children and adolescents suffered from mental disorders in their life at some point of time. Around 10% of people suffered from severe emotional disorders at some point in their life. Therefore, the rising cases of mental disorders across the globe is a major factors that propels the growth of the global behavioral rehabilitation market. Moreover, the rising number of service providers, growing expenditure on healthcare, and rising awareness regarding the mental health disorders among the population are several important factors that fosters the market growth across the globe.

We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1377

GBehavioral Rehabilitation Market Potential

As per the WHO, one in four people from across the globe are bound to be affected by some form of mental disorder and at present around 450 mn people are affected from some form of mental condition. This has resulted in the placement of mental disorders as one of the leading causes of disability or ill health around the globe. While treatments are available, only two third people come forward to seek help, states the WHO report.

The behavioral rehabilitation market is expected to grow as the number of people dealing with stress and high level emotions, resulting in behavioral diseases is increasing by the day. People suffering from depression and substance abuse have increased and this will benefit the global behavioral rehabilitation market. The market is likely to grow as more players are entering in the market to fill the gap between demand and supply. Leading players are participating in mergers and acquisitions so as to expand their reach worldwide. Players are concentrating on offering outpatient services, which are being increasingly preferred over healthcare settings, due to their cost effectiveness.

Why should you invest in this report?

If you are aiming to enter the global behavioral rehabilitation market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for behavioral rehabilitation are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Some of the prominent players in the global behavioral rehabilitation market include:

  • Allergan, Inc.
  • Novartis AG
  • Taro Pharmaceutical Industries
  • Perrigo Company plc
  • Zynerba Pharmaceuticals
  • Apotex Inc.
  • Sandoz AG
  • Strides Arcolab Ltd.
  • TOLMAR Pharmaceuticals, Inc.
  • Limbix

Market Segmentation:

By Disorder Type

  • Mood Disorders
  • Anxiety Disorders
  • Personality Disorders
  • Substance Abuse Disorders
  • Attention Deficit Disorders

By Application

  • Outpatient
  • Inpatient
  • Residential

Regional Analysis:

The geographical analysis of the global behavioral rehabilitation market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.

The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global behavioral rehabilitation Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).

Key Questions Answered by the Report:

  • What will be the size of the global behavioral rehabilitation market in 2030?
  • What is the expected CAGR for the behavioral rehabilitation market between 2021 and 2030?
  • Which are the top players active in this global market?
  • What are the key drivers of this global market?
  • How will the market situation change in the coming years?
  • Which region held the highest market share in this global market?
  • What are the common business tactics adopted by players?
  • What is the growth outlook of the global behavioral rehabilitation market?

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Behavioral Rehabilitation Market 

5.1. COVID-19 Landscape: Behavioral Rehabilitation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Behavioral Rehabilitation Market, By Disorder

8.1. Behavioral Rehabilitation Market, by Disorder Type, 2021-2030

8.1.1. Mood Disorders

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Anxiety Disorders

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Personality Disorders

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Substance Abuse Disorders

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Attention Deficit Disorders

8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Behavioral Rehabilitation Market, By Application

9.1. Behavioral Rehabilitation Market, by Application, 2021-2030

9.1.1. Outpatient

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Inpatient

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Residential

9.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Behavioral Rehabilitation Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.1.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.1.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.2.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.2.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.3.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.4.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.5.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Disorder (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

Chapter 11. Company Profiles

11.1. Allergan, Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Novartis AG

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Taro Pharmaceutical Industries

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Perrigo Company plc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Zynerba Pharmaceuticals

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Apotex Inc.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Sandoz AG

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Strides Arcolab Ltd.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. TOLMAR Pharmaceuticals, Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Limbix

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1377

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Post a Comment

0 Comments